Cerus Corp. is a biomedical products company, which is engaged in developing and commercializing the INTERCEPT blood system. The INTERCEPT blood system is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. It markets and sells the INTERCEPT blood system for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
Cerus call option trades that are bought on or above the market's asking price OR put trades that are sold on or less than the market's bid price - expecting a move to the updside.
Cerus put option trades that are bought on or above the market's asking price OR call trades that are sold on or less than the market's bid price - expecting a move to the downside.